NCT02003495View on ClinicalTrials.gov

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

2,195

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

October 31, 2014

Conditions
Meningitis
Interventions
BIOLOGICAL

MCV-ACYW135 Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

MPV-ACYW135 Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

MPV-A Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

MCV-AC Vaccine Group

0.5ml, intramuscular

BIOLOGICAL

Hib Vaccine Group

0.5ml, intramuscular

Trial Locations (1)

Unknown

Henan Provincial Center for Disease Control and Prevention, Zhengzhou

Sponsors
All Listed Sponsors
lead

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY